Back

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ahmed Elmorsy

Faculty Of Medicine - Tanta University, Tanta (Egypt)

3 More presentations in this session

Presentation thumbnail
Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy
Doctor A. Milazzo (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources